Primaquine is a medication used to treat and prevent malaria and to treat Pneumocystis pneumonia. Specifically it is used for malaria due to Plasmodium vivax and Plasmodium ovale along with other medications and for prevention if other options cannot be used. Technically, primaquine is an 8-aminoquinoline active against hepatic stages of Plasmodium and is administered orally as the phosphate salt; it provides radical cure by targeting dormant hypnozoites in the liver and reduces relapse risk when combined with a blood schizonticide. Important clinical considerations include assessment of glucose-6-phosphate dehydrogenase activity before use because primaquine can induce dose-dependent hemolysis in deficient individuals, metabolic activation via hepatic cytochrome P450 enzymes to oxidative metabolites that mediate antiparasitic activity, and dosage adjustments for renal or hepatic impairment as guided by clinical protocols.
Parent: Primaquine
Parent: Primaquine
Parent: Primaquine
Typical quality specifications for primaquine drug substance and formulated products control related substances and degradation products; common related compounds and degradants include desethyl-primaquine, 8-hydroxyprimaquine, primaquine N-oxide, and oxidative dimers and ring-opened products. Industry practice often sets individual unspecified impurity limits at 0.1 to 0.5 percent w/w and a total related substances limit in the range of 1.0 to 2.0 percent w/w, with lower limits such as 0.05 to 0.1 percent applied for known or potential genotoxic impurities; residual solvents, heavy metals, and assay acceptance criteria follow ICH Q3A, Q3C and Q3D guidance as applicable. Identification, quantitation and stability-indicating methods using HPLC with appropriate reference standards and mass spectrometric confirmation are standard for impurity control.
Primaquine is used to eradicate hepatic hypnozoites of Plasmodium vivax and Plasmodium ovale to prevent relapses, as part of radical cure regimens in combination with a blood schizonticide, for malaria chemoprophylaxis when other options are unsuitable, and as an adjunctive agent in treatment of Pneumocystis pneumonia in specific clinical settings.
A 14-day course is prescribed to ensure complete elimination of dormant liver hypnozoites of P. vivax and P. ovale, because shorter courses have higher relapse rates; the prolonged daily exposure allows cumulative metabolic activation and sustained oxidative stress against tissue parasite stages required for radical cure while balancing tolerability and hemolysis risk.
Primaquine should not be used in individuals with known glucose-6-phosphate dehydrogenase deficiency, pregnant women because fetal G6PD status is unknown, neonates, and patients with a history of severe hypersensitivity to primaquine; caution and specialist consultation are required for those with significant hepatic or renal impairment.
Primaquine is metabolized in the liver to active oxidative metabolites that generate reactive oxygen species and disrupt parasite mitochondrial function and electron transport; these metabolites preferentially target extraerythrocytic hepatic stages including hypnozoites and prevent relapse, while the parent compound has limited blood-stage activity.
